By Fineline Cube 
Chinese firms Ningbo Health Gene Technologies Co., Ltd. and Biofast Biotechnology Co., Ltd. announced late last week that they have entered into a strategic cooperation agreement. The partnership focuses on genetic testing for Fragile X syndrome, spinal muscular atrophy (SMA), and other genetic disorders, aiming to jointly advance the clinical application of precision medicine in the prevention and control of hereditary diseases.
About Ningbo Health Gene Technologies
Established in August 2011, Ningbo Health Gene Technologies is a high-tech enterprise specializing in the R&D, production, sales, and service of medical laboratory technologies and related products. The company brings a wealth of experience and technical expertise to the collaboration.
About Biofast Biotechnology
Biofast Biotechnology is an innovative biotech company engaged in molecular medicine technologies. The company focuses on the prevention, screening, and diagnosis of maternal, child, and genetic diseases. Its expertise in molecular diagnostics will play a crucial role in the partnership.
Collaboration Objectives
The collaboration aims to leverage the strengths of both companies to enhance the clinical application of genetic testing. By combining their resources and expertise, Ningbo Health Gene and Biofast Biotechnology will work to improve the prevention and control of hereditary diseases through precision medicine.-Fineline Info & Tech